Background {#Sec1}
==========

*Escherichia coli* (*E.coli*) usually colonizes the animal gastrointestinal tract as a commensal bacterium, and only a small number of strains are pathogenic. Enterotoxigenic *E.coli* (ETEC) represents one of these pathotypes that cause a variety of enteric and extraintestinal diseases in humans and animals \[[@CR1]\]. ETEC is spread by the fecal-oral route with food and water being the principal sources of infection \[[@CR1]\]. In humans, ETEC is the main cause of bacterial diarrhea in adults and children in developing countries and is also a leading cause of traveler's diarrhea \[[@CR2]\]. In pigs, enteric diseases caused with ETEC may result in significant economic losses due to morbidity, mortality, cost for treatments, decreased weight gain, vaccinations, and feed supplements \[[@CR3]\].

Apramycin (APR), an aminoglycoside antibiotic, has been used exclusively for the treatment of *E.coli* infections in swine, cattle, sheep, poultry, and rabbits around the world since the early 1980s and was approved for use in China in 1999 \[[@CR4]\]. Recently, many research papers have demonstrated that apramycin has significant in vitro activity against multidrug-, carbapenem- and aminoglycoside-resistant *E.coli* isolated in hospitals. And its excellent breadth of activity renders apramycin a promising drug candidate for the treatment of systemic Gram-negative infections \[[@CR5]--[@CR11]\]. The first resistant *E. coli* strain was detectable in nature shortly after the application of APR \[[@CR12]\]. It has been determined to date that two resistance genes confer resistance to APR in *E. coli*. One is AAC (3)-IV, which encodes an aminoglycoside 3-N-acetyltransferase type IV enzyme \[[@CR13]\]. The other is NpmA, which was identified in a clinical *E. coli* strain and encodes a 16S rRNA m1A1408 methyltransferase \[[@CR14]\]. Moreover, another APR resistance gene, apmA, was detected in bovine methicillin-resistant *Staphylococcus aureus* (MRSA) of sequence type 398 in 2011 and encodes for a protein of 274 amino acids \[[@CR15]\]. APR resistance has been also detected in *E.coli* clinical isolates of hospitalized patients despite it has not been used in human medicine \[[@CR16]\]. The horizontal transfer of the APR resistance gene *aac(3)-IV* results in the dissemination of APR-resistance *E. coli* isolates between animals and humans \[[@CR17]\]. In addition, cross-resistance between APR and other aminoglycosides such as gentamicin (GEN) and tobramycin for the treatment of severe infections in humans has been well documented \[[@CR18], [@CR19]\]. Previous study reported that pigs may have been an important reservoir for GEN-resistance bacteria transfer to humans \[[@CR20]\]. Considering the importance of GEN in human medicine, improper use of APR in animals contributing to increased resistance is of great concern.

Wild-type cutoff values (CO~WT~) are the useful tools available to laboratories performing susceptibility testing and to clinicians treating infections. In addition, the tools also provide alternative means for monitoring the emergence of drug resistance in any given bacterial species \[[@CR21]\]. A statistical method was a more scientific method which has been adopted by the Clinical and Laboratory Standards Institute (CLSI) as a standard method for CO~WT~ establishment \[[@CR22], [@CR23]\]. The purposes of the present study were (i) to develop CO~WT~ of APR against *E.coli* using a statistical method recommended by CLSI and (ii) to investigate the prevalence of genes that confer resistance to APR in *E. coli*.

Results {#Sec2}
=======

Antibacterial susceptibility testing {#Sec3}
------------------------------------

The original MICs distributions and MICs cumulative distributions of APR are presented in Fig. [1](#Fig1){ref-type="fig"}, MICs for APR against 1230 *E.coli* isolates (858 isolated, 372 donated) were in the range of 0.5 to 256 μg/mL. The percentage of *E. coli* isolates at each MIC (0.5, 1, 2, 4, 8, 16, 32, 64, 128, and 256 μg/mL) were 0.08, 0.08, 0.16, 2.93, 31.14, 38.86, 12.85, 2.03, 1.46, and 10.41%. The MIC~50~ and MIC~90~ were 16 and 64 μg/mL, respectively. Fig. 1**a**: The original MICs distributions; **b**: cumulative MICs distributions of APR against *E.coli*

Establishment of CO~WT~ {#Sec4}
-----------------------

The MIC distributions (1--64 μg/mL) for APR were statistically consistent with a normal distribution (skewness = 0.194 and kurtosis = 0.386). Non-linear regression curve fitting of cumulative log~2~ MIC data was selected as the preferred method for determining the means and standard deviations of MIC distributions owing to the normal (Gaussian) distribution is widely accepted. The process involves fitting an initial subset and generating estimates (in log2) of the strain number, mean and standard deviation in the subset. Repeat this process by reducing the previous subset in each successive column to create the next subset, and repeat the curve fitting until it is clear that there is a subset in which the absolute difference between the true and estimated separation numbers is the smallest. The optimum MIC range from 0.5 to 256 μg/ml was obtained from non-linear regression, the five subsets examined demonstrated that the subset 'MIC = 32 μg/ mL' gave the minimum difference (Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). The probability of an MIC at 32 μg/ml was 99.18%, which encompassed 95% of the WT isolates according to the NORMDIST function in Microsoft Excel (Table [2](#Tab2){ref-type="table"}). As a result, the CO~WT~ was defined as 32 μg/mL. Table 1Optimum non-linear least squares regression fitting of pooled MICs (μg/mL) for apramycin and *E.coli*Subset fittedNumber of isolatesMean MIC (log2)Standard deviation (log2)TRUEEst.Diff.ASEEst./ASE95% CIbEst.ASEEst./ASE95% CIaEst.ASEEst./ASE95% CIb≤25612301127− 10325.6144.006251066 to 11883.30.0812540.57853.105 to 3.4890.850.11077.662150.5863 to 1.110≤12811021085−178.104133.88451066 to 11053.240.02282141.93693.183 to 3.2950.780.0311225.041770.7032 to 0.8555≤6410841075−98.468126.94851054 to 10973.230.02011160.41773.174 to 3.2770.760.0271328.164390.6944 to 0.8339≤32b10591063411.989.327731030 to 10963.210.02189146.64233.149 to 3.2710.750.0286726.037670.6669 to 0.8260≤16901981807.849125.0223956.3 to 10063.110.009864315.38933.079 to 3.1420.640.0135247.204140.5952 to 0.6812Est., non linear regression estimate of value; Diff., estimate of N minus true N; ASE, asymptotic standard error; Est./ASE, estimate divided by asymptotic standard errora 95% CI of estimate of valueb This subset gave the smallest difference between the estimate and true number of isolates in the subsetFig. 2Iterative non-linear regression curve fitting with decreasing subsets. X axis = Log~2~MIC, Y axis = numbers of isolates. Numbers below each graph are the values for the true number of isolates included in the dataset (True n), the non-linear regression estimate (Estimated n) and the difference between these two values of n (Difference). O = observed numbers; solid line = fitted curveTable 2The probability estimation of CO~WT~ with NORMDIST function in microsoft excelOptimum MIC (μg/mL)Log~2~ Mean MICMean MICLog~2~SDHigh cut-off (μg/mL)Probability of a higher value≤2563.219.250.7465256100.00%≤1283.219.250.7465128100.00%≤643.219.250.74656499.99%≤32^a^3.219.250.74653299.18%≤163.219.250.74651685.50%^a^the wild type cut-off value

The prevalence of APR resistance genes {#Sec5}
--------------------------------------

A total number of 310 *E.coli* clinical isolates containing different MIC subsets (0.5-256 μg/mL) were conveniently selected for the detection of three resistance genes (*aac(3)-IV*; *npmA*; *apmA*) in *E. coli* by PCR. The prevalence of APR resistance genes presented in Table [3](#Tab3){ref-type="table"}. All the 310 *E.coli* clinical isolates were negative for *npmA* and *apmA* gene by PCR. The only resistance gene in *E.coli* that confer resistance to APR is *aac(3)-IV* in this study. The prevalence of *aac(3)-IV* gene was 91.59% (98/107) in the subset 'MIC = 256 μg/ mL'; was 64.71% (11/17) in the subset 'MIC = 128 μg/ mL'; was 36.36% (8/22) in the subset 'MIC = 64 μg/ mL'; was 1.14% (1/88) in the subset 'MIC = 32 μg/ mL' and was 0 in the subset 'MIC = 0.5-16 μg/ mL'. The percentage of *aac(3)-IV* gene in different MIC subsets is shown in Fig. [3](#Fig3){ref-type="fig"}. Table 3The prevalence of resistance genes that confer resistance to APR in *E. coli*MIC subset of APR (μg/mL)^a^Total isolatesResistance gene (%)Positive no. of *aac(3)-IV*Positive no. of *npmA*Positive no. of *apmA*25610798 (91.59%)0 (0)0 (0)1281711 (64.71%)0 (0)0 (0)64228 (36.36%)0 (0)0 (0)32881 (1.14%)0 (0)0 (0)16320 (0)0 (0)0 (0)8200 (0)0 (0)0 (0)4200 (0)0 (0)0 (0)220 (0)0 (0)0 (0)110 (0)0 (0)0 (0)0.510 (0)0 (0)0 (0)Fig. 3Percentage of *aac(3)-IV* gene in different MIC subsets

Discussion {#Sec6}
==========

APR, an aminoglycoside antibiotic, was used in veterinary therapy and animal husbandry in the early 1980's in several European countries and was approved to use in China since 1999 \[[@CR4]\]. However, a recent study demonstrated that APR is a promising drug candidate for the treatment of systemic Gram-negative infections that are resistant to treatment with other aminoglycoside antibiotics by evaluating the in vitro activity of APR against multidrug-, carbapenem- and aminoglycoside resistant Enterobacteriaceae and *Acinetobacter baumannii* in patient from Europe, Asia, Africa and South America \[[@CR6]\]. In this study, the results that 171 isolates among the 1230 *E.coli* clinical isolates had MICs ≥64 μg/ mL were similar to the previous study \[[@CR24]\]. Resistant *E. coli* are generally isolated from diseased pigs in our study, and *E. coli* from pigs may be an important reservoir for transfer of APR-resistance genes or APR-resistant bacteria to humans \[[@CR20]\]. Marshall and Levy, 2011 summarized the evidence from animal on farms to human transfer of resistant bacteria. One is to acquire resistance by direct contact with animals, and the other is the spread of antibiotic resistance through the food chain \[[@CR25]\]. The effect of antimicrobial usage on the prevalence of resistant bacteria in animals is significant \[[@CR26]\].

Phenotypic resistance is commonly interpreted according to the clinical standards and recommended breakpoints from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) or the CLSI. For aminoglycosides, the MIC breakpoints of amikacin, GEN, netilmicin and tobramycin were established by EUCAST, and the MIC breakpoints of netilmicin, kanamycin, amikacin, tobramycin and GEN were established by CLSI. However, the MIC breakpoint of APR was not established by either EUCAST or CLSI. To set breakpoints required a combination of MIC values, pharmacokinetic/pharmacodynamic relationship and clinical outcome data \[[@CR21]\]. However, it is very difficult and expensive to generate this kind of data required for breakpoint determination. The CO~WT~ is a useful tool for the interpretation of antimicrobial susceptibility testing results conducted in laboratories \[[@CR21]\]. In this study, the CO~WT~ was defined as ≤32 μg/mL by using a statistical method recommended by CLSI and was similar with that the epidemiological cut-off value (ECOFF) routinely used for APR was \>16 μg/ mL by the Laboratory of Swine diseases, Kjellerup, Denmark and by the Danish Veterinary Institute, Frederiksberg, Denmark \[[@CR27]\]. Different use of apramycin in pigs and chickens results in different susceptibility of clinical *E. coli* strains to apramycin. Tian et al. 2019 reported that "from 2016 to 2018, a total of 1412 *E. coli* from chickens were identified in 10 Chinese provinces. MIC ~50~ and MIC ~90~ for apramycin against *E. coli* (0.5\~256 μg/mL) were 8 and 16 μg/mL, respectively." \[[@CR28]\]. They conclude that the ECV (CO~WT~) for APR in *E. coli* is 16 μg/mL. The percentage of *E. coli* isolates at each MIC (0.5 to 256 μg/mL) is very different between Tian et al. 2019 and this study. Therefore, we think that the CO~WT~ (ECV) different form Tian et al. 2019 is reasonable.

To date, it has been determined that two resistance genes in *E. coli* (*aac(3)-IV*, *npmA*) confer resistance to APR \[[@CR13], [@CR14]\]. The gene *aac(3)-IV* is the only identified gene causing enzymatic cross-resistance between APR and GEN \[[@CR29]\]. GEN is a critically important drug and is generally combinated with beta-lactam as the first choice antimicrobial for severe human infections \[[@CR19]\]. In this study, the high prevalence of *aac(3)-IV* gene was observed in the resistant *E.coli* isolates, which was consistant with other previous studies \[[@CR4], [@CR19], [@CR30]--[@CR32]\]. The *npmA* gene, confers high resistance to many aminoglycoside types upon the host *E. coli*, was originally found in an *E.coli* strain isolated in 2003 from the urine of an inpatient in a general hospital in Japan \[[@CR14]\] and did not appear in the scientific literature until August 2017 from China \[[@CR33]\]. The *npmA* gene was not detected in any samples in this study, which consistant with other previous study \[[@CR34]\]. The *apmA* gene was at first detected in bovine methicillin-resistant *Staphylococcus aureus* (MRSA) of sequence type 398 in 2011 \[[@CR15]\] and was not found in any isolates in our study. Due to only the *aac(3)-IV* gene was found in all APR resistant isolates tested, suggesting that it is the predominant gene responsible for this resistance pattern in the pigs. The risk of transfer of APR/GEN cross-resistant resistant gene *aac(3)-IV* in *E.coli* from animals to humans is of great concern.

Conclusion {#Sec7}
==========

Given the lack of interpretion criteria of APR susceptibility testing, the CO~WT~ (≤ 32 μg/mL) for APR against *E.coli* was established by using a statistical method recommended by CLSI in this study. The prevelance of APR resistance gene *aac(3)-IV* mainly concentrated in these MIC subsets "MIC ≥ 64 μg/ mL", which indicates that the CO~WT~ established in our study is reliable. The CO~WT~ offers guidance for APR susceptibility testing of *E.coli* isolated from animals.

Methods {#Sec8}
=======

Isolates {#Sec9}
--------

The rectal swabs collected on each visit from the target animals were pooled and tested as one analytical sample. A total of 1230 *E.coli* isolates were used in the study, which including 858 isolates identified from rectal swabs of pigs in different province in China by using the biochemical identification and PCR method according to 'Bergey's Manual of Determinative Bacteriology' \[[@CR35]\]: Heilongjiang (*n* = 293), Jilin (*n* = 151), Liaoning (*n* = 238), Henan (*n* = 97), Shandong (*n* = 30), Hubei (*n* = 20), and Yunnan (n = 29) from June 2014 to April 2017, and 372 *E.coli* strains were respectively donated by National Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences (*n* = 108), Husbandry and Veterinary College, Jilin University (*n* = 112), and College of Animal Husbandry and Veterinary Science, Henan Agricultural University (*n* = 152). All of the bacterial isolates were confirmed by polymerase chain reaction (PCR) \[[@CR36]\].

Chemicals and reagents {#Sec10}
----------------------

Pure powder of APR was purchased from Zhejiang Hisun Pharmaceutical Co., Ltd., Taizhou, China. MacConkey medium, eosin-methylene blue medium, Mueller-Hinton (MH) broth, and MH agar were supplied form Qingdao Hope Bio-Technology Co., Ltd., Qingdao, China. Premix Taq™ Version 2.0 plus dye and DL1000 DNA Marker were obtained from Takara Biotechnology Co., Dalian, China. All primers used in the study were synthesized by the Sangon Biotech Co., Ltd., Shanghai, China.

Antibacterial susceptibility testing {#Sec11}
------------------------------------

Broth microdilution testing was performed according to the CLSI document M07-A9 \[[@CR37]\] at the following laboratories: Department of Microbiology, Department of Pharmacology and Toxicology, and Pharmacy Department in Northeast Agricultural University, Harbin, China. APR stock solution of 5120 μg/mL was prepared. Working solutions in plates were prepared by two-fold serial dilutions in MH broth. Finally, each well of 96 well plates contains approximately 5 × 10^5^ CFU/mL *E.coli* and APR concentrations ranged from 0.5 to 256 μg/mL. Plates were placed in a constant temperature incubator at 37 °C for 20 h. Quality control (QC) isolate *E.coli* ATCC 25922 (purchased from the NATIONAL CENTER FOR MEDICAL CULTURE COLLECTIONS, Beijing, China) was used on each day of testing as recommended by CLSI \[[@CR37]\]. Only those results, for which the QC MICs were within the established reference range (4-8 μg/mL), were used in the study \[[@CR38]\]. All MICs determinations were performed in triplicate.

Data analysis {#Sec12}
-------------

The definitions of the subsets, lognormal distribution, skewness, kurtosis, and CO~WT~ are presented in Table [4](#Tab4){ref-type="table"}. The MICs were transformed into log~2~ values in order to analyze the MIC distributions. The kurtosis and skewness of each MIC distribution were tested. To confirm the presence of more than one MIC distribution, frequency distributions of MIC data were analyzed by nonlinear least squares regression analysis based on the following Cumulative Gaussian Counts equation: Z = ((X-Mean))/SD, Y=N\*zdist(z) according to the previous study \[[@CR41]\], in which the Mean is the average of the original distribution, from which the frequency distribution was created; SD is the standard deviation of the original distribution (calculated by Graphpad prism 6.0 software, San Diego, CA). Three parameters, the total number (N) in the presumed unimodal distribution, the mean, and SD (both log~2~) were estimated. N was estimated rather than taken as a constant in the regression, because of the desire to fit the data to the distribution without assuming that N truly contained only wild-type isolates \[[@CR22]\]. The NORMINV and NORDIST functions in Microsoft Excel were used to set the WT distribution cutoffs which were used to determine the MIC that encompass at least 95% of that distribution \[[@CR22], [@CR42]\]. Table 4Definitions of the terminology used in this studyTerminologyDescriptionReferenceSubsetsSubsets of data extracted from datasets\[[@CR22]\]Lognormal DistributionA frequency (probability) distribution where the data are distributed in a Gaussian (normal) manner after the data points have been converted to logarithms.\[[@CR22]\]SkewnessLack of symmetry in a frequency distribution.\[[@CR22]\]KurtosisExcessive peaking or flattening of a frequency distribution when compared with the normal distribution.\[[@CR22]\]CO~WT~CO~WT~ also known as the epidemiological cutoff (ECV), defined as the highest susceptibility endpoint of the wild-type (WT) population MIC, has been shown to detect the emergence of in vitro resistance or to separate WT isolates (without known mechanisms of resistance) from non-WT isolates (with mechanisms of resistance and reduced susceptibilities to the antibacterial agent being evaluated). CO~WT~ are calculated by taking into account the MIC distribution, the modal MIC of each distribution, and the inherent variability of the test (usually within one doubling dilution) and should encompass ≥95% of isolates.\[[@CR22], [@CR39], [@CR40]\]

Molecular characterisation of mechanisms of resistance to APR {#Sec13}
-------------------------------------------------------------

A total number of 310 *E.coli* strains from different MIC subsets (0.5--256 μg/mL) were conveniently selected for the detection of resistance genes in *E. coli* that confer resistance to APR by PCR. The primers used in this study are presented in Table [5](#Tab5){ref-type="table"}. Genomic DNA was extracted using a TIANamp Bacteria DNA Kit (TIANGEN BIOTECH (BEIJING) CO., LTD.) according to the manufacturer's instructions. Then, 2 μL (400 ng/μL) was added to a reaction mixture containing 25 μL Premix TaqTM Version 2.0 plus dye, 13 μL sterile ddH~2~O, 5 μL 10 μM primer F and 5 μL 10 μM primer R. Amplification conditions were 94 °C for 5 min, followed by 30 cycles of 94 °C for 30 s, 55 °C for 30 s (52 °C for *apmA*) and 72 °C for 1 min, and a final elongation at 72 °C for 10 min. PCR products were analysed on 1.5% (w/v) agarose gelsstained with ethidium bromide. The amplified products were sequenced by the Sangon Biotech Co., Ltd., Shanghai, China. *E. coli* ATCC 25922 strains was used as negative controls. Table 5The primers used in the detection of APR resistance genes and expected amplicon sizesGeneDNA sequence (5′--3′)Product (bp)Reference*aac(3)-IVaac(3)-IV* F*aac(3)-IV* RTCGGTCAGCTTCTCAACCTTGATGATCTGCTCTGCCTGTG314\[[@CR43]\]*npmAnpmA* F*npmA* RCTCAAAGGAACAAAGACGGGAAACATGGCCAGAAACTC641\[[@CR43]\]*apmAapmA* F*apmA* RCGTTTGCTTCGTGCATTAAATTGACACGAAGGAGGGTTTC656\[[@CR15]\]

*E.coli*

:   *Escherichia coli*

ETEC

:   Enterotoxigenic *E.coli*

APR

:   Apramycin

GEN

:   Gentamicin

CO~WT~

:   Wild-type cutoff values

CLSI

:   Clinical and Laboratory Standards Institute

EUCAST

:   European Committee on Antimicrobial Susceptibility Testing

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yuqi Yang and Tianshi Xiao contributed equally to this work.

We would like to thank the following organizations for kindly donating *E. coli* strains: National Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences; Husbandry and Veterinary College, Jilin University; and College of Animal Husbandry and Veterinary Science, Henan Agricultural University.

XYZ conceived of the study and participated in its design and coordination and helped to draft the manuscript. YQY design the experiment, completed the experiments, make tables and figures and draft the manuscript. TSX, JRL, PC, FLL, HXY and RML help to carried out the bacteria isolation, the antibacterial susceptibility testing and PCR, IM revised the manuscript. All authors read and approved the final manuscript.

This study was funded by the National Science and Technology Project and National 13th Five-Year Science and Technology Project (prevention and control of major epidemics and comprehensive research and development of safe and efficient aquaculture of livestock and poultry, 2016YFD0501310). The funders had no role in the design of the study and collection, analysis and interpretation of data and in writing the manuscript.

The datasets used and analyzed in this study are available from the corresponding author on reasonable request.

All experimental work was performed with full consideration of animal welfare. Research ethical approval was granted by the Northeast Agriculture University Animal Ethics Committee. Prior to the collection of fecal samples, individual written informed consent for the use of samples was obtained from all of the pig owners.

Not applicable.

The authors declare that they have no competing interests.
